PRX 106

Drug Profile

PRX 106

Alternative Names: Anti-TNF therapeutic - Protalix Biotherapeutics; Anti-tumour necrosis factor therapeutic - Protalix Biotherapeutics; OPRX 106; pr-anti-TNF; PRX-106

Latest Information Update: 05 Dec 2016

Price : $50

At a glance

  • Originator Protalix Biotherapeutics
  • Developer Protalix BioTherapeutics
  • Class Recombinant fusion proteins
  • Mechanism of Action Interferon gamma inhibitors; Interleukin 10 stimulants; Regulatory T-lymphocyte stimulants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammatory bowel diseases

Highest Development Phases

  • Phase II Ulcerative colitis
  • Preclinical Autoimmune disorders; Crohn's disease; Fatty liver; Hepatitis; Inflammatory bowel diseases; Non-alcoholic steatohepatitis; Rheumatoid arthritis

Most Recent Events

  • 30 Nov 2016 Protalix initiates enrolment in a phase II trial for Ulcerative colitis in Israel (PO)
  • 01 Sep 2016 Phase-II clinical trials in Ulcerative colitis in Israel (PO) (NCT02768974)
  • 09 May 2016 Protalix BioTherapeutics files the protocol for a phase II trial of PRX 106 for the treatment of patients with Ulcerative colitis in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top